A recently published research article from Regenerative Medicine Institute (REMEDI) & Centre for Cell Manufacturing Ireland (CCMI) at University of Galway and Orbsen Therapeutics Ltd., Galway in collaboration with multiple European partners reports promising results of an early-phase clinical trial of a mesenchymal stromal cell product in diabetic kidney disease.

In January 2023 this article explained the promising results that this novel cell therapy shows with Diabetes Type 2 Patients with Kidney Damage. The publishing of this paper is a successful development and clinical translation of a novel cell therapy developed in Ireland.

Find the full paper as an Open Access publication at the website of the Journal of the American Society of Nephrology in the link below.